About Bioline  All Journals  Testimonials  Membership  News  Donations

Indian Journal of Cancer
Medknow Publications on behalf of Indian Cancer Society
ISSN: 0019-509X
EISSN: 1998-4774
Vol. 48, No. 4, 2011, pp. 438-445
Bioline Code: cn11122
Full paper language: English
Document type: Review Article
Document available free of charge

Indian Journal of Cancer, Vol. 48, No. 4, 2011, pp. 438-445

 en Nilotinib as first-line therapy for chronic myeloid leukemia
Vaid, A


Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.

Tyrosine kinase inhibitor, response, safety, overcoming resistance

© Copyright 2011 - Indian Journal of Cancer
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2022, Site last up-dated on 19-Jan-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil